Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models

Por Duignan, Inga J, Corcoran, Erik, Pennello, Anthony, Plym, Mary Jane, Amatulli, Michael, Claros, Nidia, Iacolina, Michelle, Youssoufian, Hagop, Witte, Larry, Samakoglu, Selda, Schwartz, Jonathan, Surguladze, David, Tonra, James R
Publicado em 2011

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Por Armand, Philippe, Janssens, Ann, Gritti, Giuseppe, Radford, John, Timmerman, John, Pinto, Antonio, Mercadal Vilchez, Santiago, Johnson, Peter, Cunningham, David, Leonard, John P., Rodig, Scott J., Martín-Regueira, Patricia, Sumbul, Anne, Samakoglu, Selda, Tang, Hao, Ansell, Stephen M.
Publicado no Blood (2021)

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Por Ansell, Stephen M., Minnema, Monique C., Johnson, Peter, Timmerman, John M., Armand, Philippe, Shipp, Margaret A., Rodig, Scott J., Ligon, Azra H., Roemer, Margaretha G.M., Reddy, Nishitha, Cohen, Jonathon B., Assouline, Sarit, Poon, Michelle, Sharma, Manish, Kato, Kazunobu, Samakoglu, Selda, Sumbul, Anne, Grigg, Andrew
Publicado no J Clin Oncol (2019)